Variation in prescribing of lipid-lowering medication in primary care is associated with incidence of cardiovascular disease and all-cause mortality in people with screen-detected diabetes: findings from the ADDITION-Denmark trial
R K Simmons, A H Carlsen, S J Griffin, M Charles, J S Christiansen, K Borch-Johnsen, A Sandbaek, T Lauritzen, R K Simmons, A H Carlsen, S J Griffin, M Charles, J S Christiansen, K Borch-Johnsen, A Sandbaek, T Lauritzen
Abstract
Aims: To examine variation between general practices in the prescription of lipid-lowering treatment to people with screen-detected Type 2 diabetes, and associations with practice and participant characteristics and risk of cardiovascular events and all-cause mortality.
Methods: Observational cohort analysis of data from 1533 people with screen-detected Type 2 diabetes aged 40-69 years from the ADDITION-Denmark study. One hundred and seventy-four general practices were cluster randomized to receive: (1) routine diabetes care according to national guidelines (623 individuals), or (2) intensive multifactorial target-driven management (910 individuals). Multivariable logistic regression was used to quantify the association between the proportion of individuals in each practice who redeemed prescriptions for lipid-lowering medication in the two years following diabetes diagnosis and a composite cardiovascular disease (CVD) outcome, adjusting for age, sex, prevalent chronic disease, baseline CVD risk factors, smoking and lipid-lowering medication, and follow-up time.
Results: The proportion of individuals treated with lipid-lowering medication varied widely between practices (0-100%). There were 118 CVD events over 9431 person-years of follow-up. For the whole trial cohort, the risk of CVD was significantly higher in practices in the lowest compared with the highest quartile for prescribing lipid-lowering medication [adjusted odds ratio (OR) 3.4, 95% confidence interval (CI) 1.6-7.3]. Similar trends were found for all-cause mortality.
Conclusions: More frequent prescription of lipid-lowering treatment was associated with a lower incidence of CVD and all-cause mortality. Improved understanding of factors underlying practice variation in prescribing may enable more frequent use of lipid-lowering treatment. The results highlight the benefits of intensive treatment of people with screen-detected diabetes (Clinical Trials Registry No; NCT 00237549).
Trial registration: ClinicalTrials.gov NCT00237549.
© 2014 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
Figures
References
- Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey SmithG. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
- National Institute of Health and Clinical Excellence (NICE) The Management of Type 2 Diabetes. London: NICE; 2008.
- Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Boggild H, Olsen J. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol. 2005;60:534–542.
- Kedward J, Dakin L. A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care. Br J Gen Pract. 2003;53(494):684–689.
- Harnick DJ, Cohen JL, Schechter CB, Fuster V, Smith DA. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. Am J Cardiol. 1998;81:1416–1420.
- Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ. 1998;317:1134–1135.
- Bradley CP. Factors which influence the decision whether or not to prescribe: the dilemma facing general practitioners. Br J Gen Pract. 1992;42:454–458.
- Lauritzen T, Sandbaek A, Carlsen AH, Borch-Johnsen K. All-cause mortality and pharmacological treatment intensity following a high risk screening program for diabetes. A 6.6 year follow-up of the ADDITION study, Denmark. Prim Care Diabetes. 2012;6:193–200.
- Murphy E, Kinmonth AL. No symptoms, no problem? Patients' understandings of non-insulin dependent diabetes. Fam Pract. 1995;12:184–192.
- Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378:156–167.
- Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care. 2004;27:727–733.
- Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353:617–622.
- Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016.
- Royal College of General Practitioners in Denmark. Type 2-Diabetes in General Practice – Diagnosis and Treatment. Copenhagen: Royal College of General Practitioners; 1999.
- UNESCO. International Standard Classification of Education. Montreal: UNESCO; 1997.
- Organisation for Economic Co-operation and Development. What are Equivalence Scales? Paris: OECD; 2008.
- Kristensen JK, Bak JF, Wittrup I, Lauritzen T. Diabetes prevalence and quality of diabetes care among Lebanese or Turkish immigrants compared to a native Danish population. Prim Care Diabetes. 2007;1:159–165.
- Guldberg TL, Vedsted P, Kristensen JK, Lauritzen T. Improved quality of Type 2 diabetes care following electronic feedback of treatment status to general practitioners: a cluster randomized controlled trial. Diabet Med. 2011;28:325–332.
- Bennett KE, Williams D, Feely J. Under-prescribing of cardiovascular therapies for diabetes in primary care. Eur J Clin Pharmacol. 2003;58:835–841.
- Berthold HK, Gouni-Berthold I, Bohm M, Krone W, Bestehorn KP. Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovascular Diabetology. 2009;8:25.
- Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 2000;321:1322–1325.
- Thomsen TF, Jorgensen T, Ibsen H, Borch-Johnsen K. Assessment of coronary risk in general practice in relation to the use of guidelines: a survey in Denmark. Prev Med. 2001;33:300–304.
- Evans JS, Harries C, Dennis I, Dean J. General practitioners' tacit and stated policies in the prescription of lipid lowering agents. Br J Gen Pract. 1995;45:15–18.
- Korgsgaard P. Spilder millioner på helbredstjek. Mere gavn end skade. Eksperter advarer mod forebyggende helbredstjek, men det er de ligeglade med i landets kommuner. Ekstra Bladet. 2013
- Olivarius NF. Ingen evidens for befolkningsbaseret screening for type 2-diabete (No evidence for population based screening for type 2 diabetes) Ugeskr Laeger. 2012;174:2032.
- Torjesen I. Government prioritises health checks for 15 million adults despite pre-election promise to scrap them. BMJ. 2013;346:f2941.
- BMJ. 2012. Too much medicine. Available at: .
- Ravnskov U. Statins as the new aspirin. Conclusions from the heart protection study were premature. BMJ. 2002;324:789.
- Rubak S, Sandbaek A, Lauritzen T, Borch-Johnsen K, Christensen B. Effect of ‘motivational interviewing’ on quality of care measures in screen detected type 2 diabetes patients: a one-year follow-up of an RCT, ADDITION Denmark. Scand J Primary Health Care. 2011;29:92–98.
- Tiv M, Viel JF, Mauny F, Eschwege E, Weill A, Fournier C. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PloS One. 2012;7:e32412.
Source: PubMed